These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 31566898)

  • 21. Lenalidomide with dexamethasone to multiple myeloma patients relapsing from bortezomib-based induction therapies: A prospective, observational study.
    Tan TD; Hong YC; Li SS; Yu JT; Sung YC; Wang PN; Teng CJ
    Chin J Physiol; 2020; 63(5):211-217. PubMed ID: 33109787
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bisphosphonates in multiple myeloma.
    Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
    Cochrane Database Syst Rev; 2010 Mar; (3):CD003188. PubMed ID: 20238320
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lenalidomide vs bortezomib maintenance choice post-autologous hematopoietic cell transplantation for multiple myeloma.
    Huang J; Phillips S; Byrne M; Chinratanalab W; Engelhardt BG; Goodman SA; Harrell SL; Jagasia M; Kassim A; Rawling KT; Savani BN; Sengsayadeth S; Cornell RF
    Bone Marrow Transplant; 2018 Jun; 53(6):701-707. PubMed ID: 29703965
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment pathways and disease journeys differ before and after introduction of novel agents in newly diagnosed multiple myeloma in Taiwan.
    Liu Y; Tang CH; Qiu H; Siggins S; Hou HA
    Sci Rep; 2021 Jan; 11(1):1112. PubMed ID: 33441901
    [TBL] [Abstract][Full Text] [Related]  

  • 25. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
    Wang A; Duan Q; Liu X; Ding K; Han Y; Zhu W; Cai X; Wu J; Sun Z
    Ann Hematol; 2012 Nov; 91(11):1779-84. PubMed ID: 22773209
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib.
    Berenson A; Vardanyan S; David M; Wang J; Harutyunyan NM; Gottlieb J; Halleluyan R; Spektor TM; Udd KA; Eshaghian S; Nassir Y; Eades B; Swift R; Berenson JR
    Ann Hematol; 2017 Mar; 96(3):449-459. PubMed ID: 27933373
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination Lenalidomide/Bortezomib Treatment Synergistically Induces Calpain-Dependent Ikaros Cleavage and Apoptosis in Myeloma Cells.
    Ganesan S; Palani HK; Balasundaram N; David S; Devasia AJ; George B; Mathews V
    Mol Cancer Res; 2020 Apr; 18(4):529-536. PubMed ID: 31915234
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bortezomib and lenalidomide as front-line therapy for multiple myeloma.
    Zou Y; Lin M; Sheng Z; Niu S
    Leuk Lymphoma; 2014 Sep; 55(9):2024-31. PubMed ID: 24067138
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Survival in older women with early stage breast cancer receiving low-dose bisphosphonates or denosumab.
    Suarez-Almazor ME; Herrera R; Lei X; Chavez-MacGregor M; Zhao H; Giordano SH
    Cancer; 2020 Sep; 126(17):3929-3938. PubMed ID: 32573777
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Morphologic Classification Is an Important Prognostic Factor in Patients with Newly Diagnosed Multiple Myeloma Treated with Bortezomib or Lenalidomide.
    Takakuwa T; Araki T; Nakamura K; Fukuyama T; Miura A; Fujitani Y; Hisanabe A; Kaieda A; Fukada E; Yamamura R
    Ann Clin Lab Sci; 2020 May; 50(3):333-341. PubMed ID: 32581022
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcome of COVID-19 infection in 50 multiple myeloma patients treated with novel drugs: single-center experience.
    Krejci M; Pour L; Adam Z; Sandecka V; Stork M; Sevcikova S; Krejci M; Knechtova Z; Kral Z
    Ann Hematol; 2021 Oct; 100(10):2541-2546. PubMed ID: 34309714
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A longitudinal computed tomography study of lenalidomide and bortezomib treatment for multiple myeloma: trabecular microarchitecture and biomechanics assessed using multidetector computed tomography.
    Takasu M; Tani C; Kaichi Y; Sakoda Y; Kiguchi M; Date S; Kuroda Y; Sakai A; Awai K
    Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):485-92. PubMed ID: 25190250
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Poor outcomes of immunoglobulin D multiple myeloma patients in the era of novel agents: a single-center experience.
    Zhao Q; Li F; Song P; Zhou X; An Z; Mei J; Shao J; Li H; Wang X; Guo X; Zhai Y
    Cancer Commun (Lond); 2019 Sep; 39(1):51. PubMed ID: 31558165
    [No Abstract]   [Full Text] [Related]  

  • 34. Frailty impairs the feasibility of induction therapy but not of maintenance therapy in elderly myeloma patients: final results of the German Maintenance Study (GERMAIN).
    Brioli A; Manz K; Pfirrmann M; Hänel M; Schwarzer AC; Prange-Krex G; Fabisch C; Knop S; Illmer T; Krammer-Steiner B; Hochhaus A; von Lilienfeld-Toal M; Mügge LO
    J Cancer Res Clin Oncol; 2020 Mar; 146(3):749-759. PubMed ID: 31788741
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adherence to Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma.
    Mian H; Fiala M; Wildes TM
    Clin Lymphoma Myeloma Leuk; 2020 Feb; 20(2):98-104.e1. PubMed ID: 31843543
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study.
    Cohen YC; Magen H; Lavi N; Gatt ME; Chubar E; Horowitz N; Kreiniz N; Tadmor T; Trestman S; Vitkon R; Rouvio O; Shvetz O; Shaulov A; Ziv-Baran T; Avivi I
    Ann Hematol; 2020 Jun; 99(6):1273-1281. PubMed ID: 32193630
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [First-line treatment of multiple myeloma].
    Breitkreutz I; Raab M; Goldschmidt H
    Internist (Berl); 2019 Jan; 60(1):23-33. PubMed ID: 30552458
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk Factors for Developing Skeletal-Related Events in Breast Cancer Patients With Bone Metastases Undergoing Treatment With Bone-Modifying Agents.
    Tanaka R; Yonemori K; Hirakawa A; Kinoshita F; Takahashi N; Hashimoto J; Kodaira M; Yamamoto H; Yunokawa M; Shimizu C; Fujimoto M; Fujiwara Y; Tamura K
    Oncologist; 2016 Apr; 21(4):508-13. PubMed ID: 26975863
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is the risk of second primary malignancy increased in multiple myeloma in the novel therapy era? A population-based, retrospective cohort study in Taiwan.
    Liu Y; Hou HA; Qiu H; Tang CH
    Sci Rep; 2020 Sep; 10(1):14393. PubMed ID: 32873831
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis.
    Bringhen S; Offidani M; Palmieri S; Pisani F; Rizzi R; Spada S; Evangelista A; Di Renzo N; Musto P; Marcatti M; Vallone R; Storti S; Bernardini A; Centurioni R; Aitini E; Palmas A; Annibali O; Angelucci E; Ferrando P; Baraldi A; Rocco S; Andriani A; Siniscalchi A; De Stefano V; Meneghini V; Palumbo A; Grammatico S; Boccadoro M; Larocca A
    Crit Rev Oncol Hematol; 2018 Oct; 130():27-35. PubMed ID: 30196909
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.